期刊文献+

替吉奥胶囊联合奥沙利铂治疗晚期大肠癌的疗效分析 被引量:10

Clinical study of S1 capsule combined with oxaliplatin in the treatment of patients with advanced colorectal carcinoma
下载PDF
导出
摘要 目的:观察替吉奥(S-1)胶囊联合奥沙利铂治疗晚期大肠癌的临床疗效和安全性。方法:采用非盲法随机对照试验。试验组18例,替吉奥(S-1)胶囊联合奥沙利铂,替吉奥(S-1)胶囊每天80 mg/m2,分2次,餐后口服,d1-14,奥沙利铂85mg/m2,静脉滴注,3h,d1,28天一周期;对照组18例,奥沙利铂85mg/m2,静脉滴注,3h,d1,亚叶酸钙200mg/m2静脉滴注,2h,d1-5,氟尿嘧啶300mg/m2静脉滴注,2h,d1-5,28天一周期。结果:试验组(CR+PR)RR 56.1%,中位生存期(MST)18.6个月,对照组(CR+PR)RR 44.4%,中位生存期(MST)16.2个月。主要不良反应为血液学毒性和胃肠道反应,试验组白细胞下降发生率66.7%对照组77.8%,试验组恶心、呕吐发生率44.4%,对照组66.7%。结论:替吉奥(S-1)胶囊胶囊联合奥沙利铂是治疗晚期大肠癌是一种安全有效的化疗方案。 Objective:To evaluate the efficacy and toxicity of S1 capsule combined with oxaliplatin in the treatment of advanced colorectal carcinoma.Methods:Using non-blinded randomized controlled trial,study group 18 cases,were treated by gonow(S-1) capsule plus oxaliplatin Platinum,gonow(S-1) capsule every day 80 mg/m2,min 2 times.In controlled group 18 cases were treated,by oxaliplatin Platinum 85mg/m2,vein drops,3h,d1,Asia folic acid calcium 200mg/ m2 vein drops,2h,d1-5,Fluoride urine pyrimidine 300mg/ m2 vein drops,2h,d1-5.Results:In study group(CR+PR) RR was 56.1%,median survival time(MST) 18.6 months.In control group(CR+PR) RR 44.4%,median survival time(MST)16.2 months.Major adverse reactions were haematological toxicity and gastrointestinal reactions.Conclusion:S1 capsule combined with oxaliplatin is effective and tolerable in the treatment of patients with advanced colorectal carcinoma.
出处 《现代肿瘤医学》 CAS 2012年第10期2104-2106,共3页 Journal of Modern Oncology
关键词 替吉奥(S-1)胶囊 奥沙利铂 晚期大肠癌 S1 capsule oxaliplatin colorectal carcinoma
  • 相关文献

参考文献13

  • 1冉飞武,张弘纲.晚期大肠癌化学治疗的新进展[J].癌症进展,2008,6(3):229-235. 被引量:15
  • 2Tournigdand C, Cervantes A, Figer A, et al. Optimoxl : a random- ized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop - and - go fashion in advanced colorectal cancer - a GERGOR study [ J ]. J Clin Oncol,2006,24 ( 3 ) : 394 - 400.
  • 3王鹏远,赵宏亮.FOLFOX4方案治疗晚期大肠癌疗效观察[J].医药论坛杂志,2010,31(7):9-10. 被引量:6
  • 4Horio T ,Tsujimoto H, Akase T, et al. Syndrome of inappropriate an- tidiuretic hormone secretion following adjuvant CDDP and 5 - FU administration in a patient with esophageal carcinoma [ J ]. Gan To Kagaku Ryoho ,2010,37 (10) :1945.
  • 5刘伟先,赵靓,刘晶,张玲玲,刘树斌.替吉奥联合奥沙利铂治疗晚期大肠癌的疗效观察[J].实用临床医药杂志(护理版),2010,14(12):54-55. 被引量:42
  • 6Rudholm T, Wallin B, Theodorsson E, et al. Release of regulatory gut peptides sematostatin, neurotensin and vasoactive intestinal peptde by acid and hyperosmolal solutions in the intestine in con- scious rats[ J]. Regul Pept,2009,152( 1 - 3 ) :8.
  • 7方伟达,陈昌南,张呈,梁文勇,潘岐作,苏铭俊,谢峰.低剂量替吉奥口服治疗放弃静脉化疗的晚期结直肠癌[J].现代肿瘤医学,2011,19(9):1823-1825. 被引量:18
  • 8陈戎,伍尚标,苏榕,李志发.胰腺癌根治术后应用吉西他滨联合替吉奥胶囊的疗效观察[J].中国普通外科杂志,2011,20(3):217-221. 被引量:17
  • 9Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curativeintent re- section of pancreatic cancer: a randomized controlled trial [ J ]. JA- MA ,2007,297 (3) :267 - 277.
  • 10Shirasaka T. Development history and concept of an oral antican- cer agent S- 1 ( TS - 1 ) : Its clinical usefulness and future vistas [ J]. Jpn J Clin 0ncol,2009,39:2 - 15.

二级参考文献100

共引文献166

同被引文献113

  • 1毛伟芳,顾秀珍.结肠镜并发肠穿孔的原因分析及其防治[J].中华消化杂志,2006,26(1):61-61. 被引量:35
  • 2汤钊猷.现代肿瘤学[M].第3版,上海:复旦大学出版社,2011:203-204.
  • 3Tournigoland C, Cervantes A, Figer A, et al. Optimoxl: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stopand-go fashion in advanced colorectal cancer-a GERGOR study[J]. J Clin Oncol,2006,24(3) :394-400.
  • 4Blum M,Suzuki A,A jani J A. A comprehensive review of S-1 in the treatment ofadvanced gastrie adenoarcinoma[J]. Future Oneol, 2011,7(6) :715.
  • 5Zang D Y,Lee B H,Park H C,et al. PhaseII study with oxaliplatin and S-1 for patients with metastatic colorectal cancer[J]. Ann Oncol,2009,20(5):892-896.
  • 6Y. komatsu Yuki,S. Sogaabe, et al. Phasell Trial of Combined Chemotherapy with I rinotecan,S-1 ,and Benvacizumab in Pa- tients with Metastatic Colorectal Cancer[J]. ESMO, 2010,5 : 1702-1708.
  • 7Tournigdand C,Cervantes A,Figer A,et al.Optimoxl:a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop and go fashion in advanced colorectal cancer a GERGOR study[J].J Clin Oncol,2006,24(3):394-400.
  • 8Horio T,Tsujimoto H,Akase T,et al.Syndrome of inappropriate antidiuretic hormone secretion following adjuvant CDDP and 5-FU administration in a patient with esophageal carcinoma[J].Gan To Kagaku Ryoho,2010,37(10):1945.
  • 9Blum M,Suzuki A,Ajani JA.A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma[J].Future Oncol,2011,7(6):715-726.
  • 10Bleiberg H.Oxaliplatin(L-OHP):a new realsty in colorectal cancer[J].BR J Cancer,1998,77(Suppl 4):1-3.

引证文献10

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部